October 20, 2008
LOS ANGELES, October 20, 2008 – KYTHERA Biopharmaceuticals, Inc. ("Kythera") announced today its participation in an investor roundtable titled, “The Future of Plastic Surgery,” co-hosted by Leerink Swann investor roundtable program and the American Society of Plastic Surgeons (ASPS). The roundtable, being held on Monday, November 3, from 8:00 a.m. until 3 p.m. EDT, will feature panel discussions by senior management executives from industry and key opinion leaders from ASPS membership. Keith Leonard, President and CEO, will be discussing KYTHERA’s products in development and their potential business impact in plastic surgery.
“KYTHERA’s lead development program, ATX-101, has the potential to be an advancement in localized fat reduction,” said Keith Leonard, President and CEO. “We are very excited to discuss this product with investors and key opinion leaders from ASPS membership during this Leerink Swann roundtable.”
KYTHERA announced in May the close of $40 Million Series C Financing led by JAFCO Co. Ltd. KYTHERA plans to use the proceeds of this financing to complete Phase 2 trials for ATX-101, an adipolytic agent being studied for minimally-invasive reduction of localized fat deposits.
Keith Leonard, President and Chief Executive Officer, will be available to discuss the Company following the roundtable. The roundtable will be held November 3, 2008, from 8:00 a.m. until 3 p.m. EDT at McCormick Place in Chicago, IL.